ABT-494 has delivered stellar results in a Phase IIb study for atopic dermatitis, scoring a big win for AbbVie $ABBV on a drug it counts as one of its most exciting late-stage blockbuster prospects.
The drug, AKA upadacitinib, handily whipped a placebo group among treatment resistant patients, with a 74% improvement in a key measure of disease severity for the group taking the high dose of their JAK1 drug. Up to 69% of the patients taking one of three doses achieved a 75% improvement.
Here’s the score on itching:
Patients treated with upadacitinib experienced 69/48/40 percent improvement in itch across the 30/15/7.5 mg upadacitinib doses, as measured by the pruritus numerical rating scale (NRS), compared to 10 percent for patients receiving placebo (p<0.001/0.001/0.01, respectively).
Those kind of data bode well for AbbVie, which is looking to tackle a field that is going through an upheaval spurred by new drugs like Dupixent. AbbVie chose to walk away from some big partnerships to focus on its in-house drug, convinced that they were on to a winner. And these numbers look better than Dupixent’s.
Just a few months ago AbbVie reported great results from its first late-stage rheumatoid arthritis study using ABT-494.
“We are excited by the results of this study, which show that upadacitinib has the potential to be an important treatment option for patients with atopic dermatitis,” said Michael Severino, executive vice president, research and development and chief scientific officer, AbbVie. “We look forward to advancing upadacitinib to Phase 3 studies in 2018. AbbVie’s continued progress across our upadacitinib clinical development program further demonstrates that selective inhibition of the JAK1 pathway may be a novel therapeutic approach across a broad range of immune-mediated diseases.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription